Prognostic value of igF-1r expression in bone and soft tissue sarcomas: a meta-analysis

License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php OncoTargets and Therapy 2015:8 1949–1955 OncoTargets and Therapy Dovepress

[1]  M. Martano,et al.  Increased expression of insulin-like growth factor-1 receptor is correlated with worse survival in canine appendicular osteosarcoma. , 2015, Veterinary journal.

[2]  K. Griffith,et al.  Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Helen X. Chen,et al.  Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group , 2015, Pediatric blood & cancer.

[4]  S. Ferrari,et al.  Prognostic and predictive role of CXCR4, IGF-1R and Ezrin expression in localized synovial sarcoma: is chemotaxis important to tumor response? , 2015, Orphanet Journal of Rare Diseases.

[5]  Y. Li,et al.  Prognostic value of pathologic fracture in patients with high grade localized osteosarcoma: A systemic review and meta‐analysis of cohort studies , 2015, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[6]  P. Meltzer,et al.  Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma , 2014, Oncogene.

[7]  P. Houghton,et al.  Insulin-Like Growth Factor 1 Receptor and Response to Anti-IGF1R Antibody Therapy in Osteosarcoma , 2014, PloS one.

[8]  Helmut Klocker,et al.  Oncogenic functions of IGF1R and INSR in prostate cancer include enhanced tumor growth, cell migration and angiogenesis , 2014, Oncotarget.

[9]  J. A. van der Laak,et al.  Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice. , 2013, European journal of cancer.

[10]  W. T. van der Graaf,et al.  IGF signaling pathway analysis of osteosarcomas reveals the prognostic value of pAKT localization. , 2013, Future oncology.

[11]  L. Qin,et al.  Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. , 2013, The Lancet. Oncology.

[12]  H. Schreuder,et al.  Prognostic and therapeutic relevance of the IGF pathway in Ewing’s sarcoma patients , 2013, Targeted Oncology.

[13]  J. Blay,et al.  Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. , 2012, European journal of cancer.

[14]  J. Mora,et al.  Activated growth signaling pathway expression in Ewing sarcoma and clinical outcome , 2012, Pediatric blood & cancer.

[15]  B. Qian,et al.  Increased expression of insulin‐like growth factor‐1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma , 2012, Journal of surgical oncology.

[16]  P. Jedlicka,et al.  A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs , 2011, Oncogene.

[17]  J. Toretsky,et al.  Investigation of the insulin‐like growth factor‐1 signaling pathway in localized Ewing sarcoma , 2011, Cancer.

[18]  S. Ferrari,et al.  Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival. , 2011, European journal of cancer.

[19]  W. R. Bishop,et al.  A Fully Human Insulin-Like Growth Factor-I Receptor Antibody SCH 717454 (Robatumumab) Has Antitumor Activity as a Single Agent and in Combination with Cytotoxics in Pediatric Tumor Xenografts , 2010, Molecular Cancer Therapeutics.

[20]  Edward S. Kim,et al.  Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development. , 2009, Cancer research.

[21]  M. van de Rijn,et al.  Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays. , 2009, Human pathology.

[22]  H. Mankin,et al.  Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines , 2009, Molecular Cancer Therapeutics.

[23]  S. de Jong,et al.  The insulin‐like growth factor system and sarcomas , 2009, The Journal of pathology.

[24]  P. Picci,et al.  Targeting insulin-like growth factor 1 receptor in sarcomas , 2008, Current opinion in oncology.

[25]  S. Sheen-Chen,et al.  Lack of prognostic value of insulin-like growth factor-1 in patients with breast cancer: analysis with tissue microarray. , 2007, Anticancer research.

[26]  M. Sydes,et al.  Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.

[27]  M. Sułkowska,et al.  Expression of the Insulin‐Like Growth Factor‐I Receptor and Proapoptotic Bax and Bak Proteins in Human Colorectal Cancer , 2004, Annals of the New York Academy of Sciences.

[28]  Mike Wilson,et al.  IGF‐1 receptor contributes to the malignant phenotype in human and canine osteosarcoma , 2004, Journal of cellular biochemistry.

[29]  G Nilsson,et al.  Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. , 1999, Cancer research.

[30]  W. Rutter,et al.  Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation , 1990, Molecular and cellular biology.

[31]  B. Brigman,et al.  Bone cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[32]  O. Larsson,et al.  Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.